Apr
23
About ZOSTAVAX Merck submit a Biologics License Application for ZOSTAVAX to the U.S. Food & Drug Administration (FDA) on April 25. The FDA will determine inwardly 60 days of that date whether it will adopt for review Merck’s standing as submitted. Merck submitted an application for acclamation in the European Union in May.
[...]
